SOFTMINING
cutting edge technologies for drugs and materials
Who We Are
SoftMining uses advanced artificial intelligence and laboratory robotics to accelerate the discovery of new drugs and biomaterials.
Our approach shifts from searching for a single “disease gene” to mapping the full biological networks that sustain a pathology.
Every computation and experiment is time-stamped, verified, and converted into reusable knowledge — ensuring that each new project starts ahead, not from zero.
Why SoftMining
Drug discovery is still slow, linear, and siloed.
We replace this model with an AI-robotic ecosystem that learns continuously, reuses every piece of knowledge, and reaches preclinical-readiness in ~6 months.
SoftMining in Numbers
AI
Platform for drug discovery
and biomaterials
What we do
Build disease-network maps by reading and linking tens of thousands of scientific articles.
Design, synthesize, and test molecules in a continuous AI-robotic loop.
Integrate all processes into ADAPT, a unified platform coordinating tools, data, teams, and partners.
Compress timelines (preclinical readiness in ~6 months), increase quality, and strengthen intellectual property protection.
The problem we solved
Drug discovery traditionally advances in linear steps: design → synthesize → test.
When a step fails, teams restart, and much of the generated data remains unstructured and unusable.
Additionally, many efforts still target single genes, while diseases are complex, multi-layer interaction systems.
SoftMining addresses these bottlenecks by integrating network biology, AI-driven design, and automated experimentation into a single continuous pipeline.
Meet ADAPT
Advanced Drug Discovery Automation Platform
A unified environment where AI, robotics, chemistry, biology, and data converge.
ADAPT coordinates tools, models, experiments, and partners into a seamless, self-updating pipeline.
What ADAPT enables:
Ultra-scale virtual screening (>10^14 molecules).
Multi-objective optimization balancing potency, selectivity, ADMET, synthesis, and cost.
Continuous integration of experiments, with real-time model updates.
Certified, traceable workflows with complete data provenance.
Cross-omics analysis through next-generation integrative frameworks.
Outcome: faster, safer, and more predictable early-stage R&D.
Clients & Partners
Our customers are pharma companies and biotech labs seeking to de-risk the drug discovery process.
PARTNERS & CLIENTS
Frequently asked questions (FAQ)
“What is a disease network?”
A map of interactions among genes, proteins, pathways, and signals. Seeing the whole helps identify where interventions have the greatest effect.
“Why do we need robots?”
They enable many experiments in little time, with consistent standards and more reliable data.
“What does it mean to ‘certify’ an experiment?”
It means stamping each step with date/time and a digital signature, and storing raw data with full history—so anyone can verify they haven’t been altered.
“If I work with SM, are my data safe?”
Yes. The platform isolates workspaces, controls access, and supports selective sharing. The partner’s intellectual property remains protected.
“Is this approach only for drugs?”
No. It also works for biomaterials, where precise properties are needed and where computations and tests generate reusable knowledge.